ReviewArthritis research & therapy2012
B-cell activating factor targeted therapy and lupus.
Review in Arthritis research & therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 36 citations in OpenAlex.
- Development of a LASSO-based machine learning model for relapse prediction in lupus nephritis.Lupus science & medicine · 2026Article
- Infectious Risks Associated with Biologic Therapies in Autoimmune, Rheumatologic and Dermatologic Diseases: A Narrative Review.Microorganisms · 2026Review
- Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.Kidney international · 2024Review
- Autoimmune hepatitis: Towards a personalized treatment.World journal of hepatology · 2024Review
- B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease.Frontiers in immunology · 2023Article
- Altered Germinal-Center Metabolism in B Cells in Autoimmunity.Metabolites · 2022Review
- BAFF Inhibition Effectively Suppresses the Development of Anti-HLA.A2 Antibody in the Highly Sensitized Mouse Model.International journal of molecular sciences · 2021Article
- BAFF Produced by Neutrophils and Dendritic Cells Is Regulated Differently and Has Distinct Roles in Antibody Responses and Protective Immunity against West Nile Virus.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Association Between Changes in BLyS Levels and the Composition of B and T Cell Compartments in Patients With Refractory Systemic Lupus Erythematosus Treated With Belimumab.Frontiers in pharmacology · 2019Article
- Immune responses induced by recombinant Lactobacillus plantarum expressing the spike protein derived from transmissible gastroenteritis virus in piglets.Applied microbiology and biotechnology · 2018Article
- Lupus pathobiology based on genomics.Immunogenetics · 2017Review
- BAFF upregulates CD28/B7 and CD40/CD154 expression and promotes mouse T and B cell interaction in vitro via BAFF receptor.Acta pharmacologica Sinica · 2016Article
- The Role of TLR4 on B Cell Activation and Anti-Journal of immunology research · 2016Review
- The clinical relevance of animal models in Sjögren's syndrome: the interferon signature from mouse to man.Arthritis research & therapy · 2015Review
- LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis.The Journal of clinical investigation · 2015Article
- Article
- B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren's syndrome: the similarities and differences.Arthritis research & therapy · 2014Article
- Metabolic reprogramming is required for antibody production that is suppressed in anergic but exaggerated in chronically BAFF-exposed B cells.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Protein microarray analysis reveals BAFF-binding autoantibodies in systemic lupus erythematosus.The Journal of clinical investigation · 2013Article
- Treatment targets in systemic lupus erythematosus: biology and clinical perspective.Arthritis research & therapy · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell activating factor (BAFF), a member of the family of TNF-like cytokines, supports the survival and differentiation of B cells. The successful development of belimumab, a human antibody targeting soluble BAFF, has marked an important milestone in the development of biologic therapy for treatment of systemic lupus erythematosus (SLE), although much remains unknown regarding the clinical utility of BAFF inhibition in SLE and other autoimmune diseases. In the present review, we provide an overview of the knowledge concerning BAFF's role in murine and human B-cell development and maturation, as well as the clinical and mechanistic effects of BAFF inhibition in human SLE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.